|
Diabetes Medication Article
BYETTA - New Class of Diabetic Drug
Byetta is a drug derived from the saliva of the Gila monster lizard. I do know one person who is taking Byetta and has better control of her blood sugar levels. The medication has even decreased her appetite. That is a benefit for her since she is overweight.
Byetta (exenatide) is the first among a new class of diabetes drugs for Type 2 Diabetes called incretin mimetics -- synthetic medications that mimic action of a hormone that spurs insulin production after a person eats and blood sugar levels rise above a certain threshold.
Traditional diabetes drugs that promote insulin production do so even if glucose levels aren't high enough, which could cause hypoglycemia (dangerously low blood sugar).
Byetta, derived from the lizard's saliva, mimics that action of the human hormone GLP-1, which prompts the body to secrete insulin and is also thought to play a role in deciding when a person feels full. This is great because it almost acts like an appetite suppressant. Common side effects of the drug were nausea and decreased appetite.
Byetta is very unique and supposedly works in a different way than pills or insulin. By helping your body produce the right amount of insulin at the right time, Byetta helps take the guesswork out of type 2 diabetes.
Byetta is used in combination with Metformin (Glucophage) and Sulfonylurea like Amaryl® (glimepiride), Glucotrol® (glipizide), Micronase® (glyburide), and others.
Byetta is an injectable medication and comes in prefilled insulin pens where you just add a small needle and inject yourself.
The price tag is not small, but with the New Medicare Prescription Plan D, you can check out your prescription plan to see if this medication is covered.
If you are on oral diabetic medications and you are not controlled, this may be an option for you. Ask your doctor. It doesn't hurt to ask.
Please remember that primary physicians don't know everything. That is not saying they are not great doctors. No one person can know everything. Just like us nurses, some specialize in heart disease or diabetes or wound care, etc. That also applies to doctors.
If you have heart problems, you should probably get a referral to a cardiologist. The same thing with Diabetes. You may want to get a referral to an endocrinologist. Check with your primary doctor and see if a referral to an endocrinologist is right for you.
You can get more information about Byetta at http://www.byetta.com
F. Kuhn, RN
specializing in Diabetes
Diabetes Testing Center
Heart News Center
Hot Home Gym Reviews
The Secret Wisdom You Have Inside
Get Rid of Your Belly fat
Lantus Insulin News
Lantus Insulin
IMPORTANT: Bing News RSS feed has moved!
Intensive basal insulin replacement, with structured insulin titration is often associated with weight gain. [8–12] Understanding the relationships of weight changes and A1C improvements associated with clinical characteristics such as A1C, duration of ...
Read moreAddition of Exenatide to Optimized Insulin Glargine in T2DM: Conclusions
A full study description has been published. [5] The study was approved by institutional review boards in accordance with the Declaration of Helsinki. Participants were on ≥20 units/day of insulin glargine, alone or plus metformin and/or pioglitazone ...
Read moreAddition of Exenatide to Optimized Insulin Glargine in T2DM: Research Design and Methods
Insulin degludec, an ultralong-acting insulin now in clinical development, proved noninferior to insulin glargine in two parallel, phase III randomized trials sponsored by the manufacturer and reported in the April 21 issue of Lancet. The new insulin was ...
Read moreInsulin Degludec Matches Insulin Glargine Efficacy
The main limitation of these basal insulins was the risk of hypoglycemia secondary to the pronounced peak often requiring snacks to "feed" the insulin. In 2001, Glargine (Lantus), given once daily, was introduced as a 24-hour relatively peakless insulin to ...
Read moreDegludec: A New Basal Insulin
Revenue from the company’s Lantus insulin jumped 21 percent to 1.12 billion euros in the quarter, led by higher sales in the U.S., China, Brazil, Russia, Mexico and Japan, Sanofi said. Sales of the cancer drug Eloxatin more than doubled to 384 ...
Read moreSanofi First-Quarter Net Climbs 13% on Genzyme, Lantus
compared to insulin glargine. Insulin degludec is an investigational compound developed by Novo Nordisk. 1,635 individuals with diabetes were enrolled to participate in the trials in order to examine insulin degludec, compared to insulin ...
Read moreUltra-Long-Acting Insulin Degludec, Two Phase 3 Studies Published
In Emerging Markets, sales of Lantus ® reached euro 181 million ... The results of the 'Northern European Database Study of Insulin and Cancer Risk' - the first of the retrospective cohort studies - have been reviewed by EMA.
Read moreSanofi: Strong performance in Q1 2012 including Genzyme contribution
We report a series of experiments forming a comprehensive characterisation of the long acting insulin analogues, glargine and detemir, in comparison with human insulin, IGF-1, and the super-mitogenic insulin, X10. Methods We measured binding of ligands to ...
Read moreMolecular Characterisation of Long-Acting Insulin Analogues in Comparison with Human Insulin, IGF-1 and Insulin X10
On 19 April 2012, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product Lantus ... where treatment with insulin is required.
Read more